PD-L1 gene amplification and focality: relationship with protein expression

被引:5
|
作者
Jardim, Denis Leonardo [1 ]
Murugesan, Karthikeyan [2 ,3 ]
Elvin, Julia A. [3 ]
Huang, Richard S. P. [3 ]
Kurzrock, Razelle [4 ,5 ]
机构
[1] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil
[2] Fdn Med Inc, Canc Genom Res, Cambridge, MA USA
[3] Fdn Med Inc, Cambridge, MA USA
[4] WIN Consortium Personalized Canc Therapy, Dept Med, San Diego, CA USA
[5] Med Coll Wisconsin, Milwaukee, WI USA
关键词
Biomarkers; Tumor; Genetic Markers; Immunohistochemistry;
D O I
10.1136/jitc-2022-006311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PD-L1 (CD274) amplification occurs in a small subset of malignancies and may predict anti-PD-1/PD-L1 immunotherapy responsiveness. We hypothesized that both copy number (CN) and focality of cancer-related PD-L1 amplifications impact protein expression, and, thus, analyzed solid tumors that underwent comprehensive genomic profiling between March 2016 and February 2022 at Foundation Medicine. PD-L1 CN alterations were detected using a comparative genomic hybridization-like method. PD-L1 CN changes were correlated with PD-L1 protein expression (DAKO 22C3 antibody) by immunohistochemistry (IHC). Overall, 60,793 samples were analyzed (most frequent histologies: lung adenocarcinoma (20%), colon adenocarcinoma (12%), lung squamous carcinoma (8%)). Using a definition of CD274 CN >= specimen ploidy +4 (6 copies), 1.21% of tumors (738/60,793) were PD-L1 amplified. Focality category distribution was as follows: <0.1 mB (n=18 (2.4%)), >= 0.1 to <4 mB (n=230 (31.1%)), >= 4 to <20 mB (n=310 (42%)), >= 20mB (n=180 (24.4%)). Lower levels of PD-L1 amplification (below specimen ploidy +4) were more frequently non-focal amplifications compared to higher levels. In addition, more focal amplification (<0.1 mB) correlated with higher PD-L1 IHC expression. Median tumor proportion score (TPS) for samples with PD-L1 amplification (ploidy >=+4) according to focality were 87.5% (<0.1 mB), 80% (>= 0.1 to <4 mB), 40% (>= 4 to <20 mB), 1% (>= 20mB). In specimens with PD-L1 ploidy less than +4, but highly focal (<0.1 mB), the 75th percentile of PD-L1 expression by TPS was 80%. Conversely, non-focal (>= 20 mB) PD-L1 amplification (ploidy >=+4) can present high PD-L1 expression (TPS >= 50%), albeit infrequently (0.09% of our cohort). In conclusion, PD-L1 expression measured by IHC is influenced by PD-L1 amplification level and focality. Further correlation between amplification, focality, protein expression and therapeutic outcome for PD-L1 and other targetable genes warrants exploration.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] PD-L1 Expression in Sarcomas
    Kosemehmetoglu, Kemal
    Ozogul, Ece
    Babaoglu, Berrin Buyukeren
    Tezel, Gaye Y. Guler
    Gedikoglu, Gokhan M.
    MODERN PATHOLOGY, 2017, 30 : 18A - 18A
  • [32] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [33] PD-L1: expression regulation
    Zhou, Yu-Jie
    Li, Guoli
    Wang, Jiyin
    Liu, Mengyuan
    Wang, Zihan
    Song, Yu
    Zhang, Xulong
    Wang, Xi
    BLOOD SCIENCE, 2023, 5 (02): : 77 - 91
  • [34] Expression of PD-L1 in mastocytosis
    Kuklinski, Lawrence F.
    Kim, Jinah
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 1010 - 1012
  • [35] PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component
    Tanigawa, Masahiko
    Naito, Yoshiki
    Akiba, Jun
    Kawahara, Akihiko
    Okabe, Yoshinobu
    Ishida, Yusuke
    Ishikawa, Hiroto
    Hisaka, Toru
    Fujita, Fumihiko
    Yasunaga, Masafumi
    Shigaki, Takahiro
    Sudo, Tomoya
    Mihara, Yutaro
    Nakayama, Masamichi
    Kondo, Reiichiro
    Kusano, Hironori
    Shimamatsu, Kazuhide
    Okuda, Koji
    Akagi, Yoshito
    Yano, Hirohisa
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (12) : 2069 - 2074
  • [36] PD-L1 gene expression in Japanese lung cancer patients
    Sasaki, Hidefumi
    Suzuki, Ayumi
    Shitara, Masayuki
    Hikosaka, Yu
    Okuda, Katsuhiro
    Moriyama, Satoru
    Yano, Motoki
    Fujii, Yoshitaka
    BIOMEDICAL REPORTS, 2013, 1 (01) : 93 - 96
  • [37] PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
    Song, Minmin
    Chen, Defeng
    Lu, Biyan
    Wang, Chenliang
    Zhang, Junxiao
    Huang, Lanlan
    Wang, Xiaoyan
    Timmons, Christine L.
    Hu, Jun
    Liu, Bindong
    Wu, Xiaojian
    Wang, Lei
    Wang, Jianping
    Liu, Huanliang
    PLOS ONE, 2013, 8 (06):
  • [38] PD-L1 and PD1 Expression in Lymphomas
    Gatalica, Zoran
    Bilalovic, Nurija
    Vranic, Semir
    Arguello, David
    Reddy, Sandeep
    Ghosh, Nilanjan
    BLOOD, 2015, 126 (23)
  • [39] PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
    Micevic, Goran
    Thakral, Durga
    McGeary, Meaghan
    Bosenberg, Marcus W.
    PIGMENT CELL & MELANOMA RESEARCH, 2019, 32 (03) : 435 - 440
  • [40] PD1 and PD-L1 expression in glioblastoma
    Berghoff, Anna Sophie
    Kiesal, Barbara
    Widhalm, Georg
    Rajky, Orsolya
    Ricken, Garda
    Woehrer, Adelheid
    Dieckmann, Karin
    Filipits, Martin
    Zielinski, Christoph
    Marosi, Christine
    Hainfellner, Johannes A.
    Preusser, Matthias
    Wick, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)